Scott Buzby

SAN ANTONIO — Obesity medications, regardless of class or generation, were associated with reduced alcohol intake among individuals participating in a telehealth weight-loss program, a speaker reported.

Sudden cardiac death among athletes, both recreational and master level, remains a public health issue, disparately affecting players of certain sports and athlete demographics, researchers reported.

CHICAGO — High year-to-year cholesterol variability was linked to increased risk for cognitive decline and dementia among older adults, a speaker reported.

SARS-CoV-2 infection and subsequent COVID-19 are linked to elevated risk for abnormal heart rhythms, and understanding underlying mechanisms and management strategies are clinically important objectives, researchers reported.

CHICAGO — Elevated risk for heart disease may arrive up to 28 years sooner for individuals with average risk factors plus diabetes and kidney disease vs. those without cardio-kidney-metabolic disease, a speaker reported.

In a cohort of English youths, those who persisted smoking tobacco from childhood to early adulthood showed significant cardiac damage by age 24 years and potentially irreversible cardiac injury, a researcher reported.

SAN ANTONIO — Tirzepatide confers significant weight loss and cardiometabolic benefits for patients with diabetes and overweight or obesity, especially for those who lose more weight earlier during treatment, a speaker reported.

CHICAGO — Use of an SGLT2 inhibitor or GLP-1 receptor agonist after stroke may improve mortality and lower subsequent risk for heart attack and another stroke, a speaker reported.

SAN ANTONIO — Semaglutide 2.4 mg was associated with reduced year-over-year health care costs, up to $6,500, among patients with overweight or obesity and heart failure, a speaker reported.

SAN ANTONIO — Utreglutide, a novel GLP-1 analog, when administered in multiple ascending doses, demonstrated sustained weight loss for weeks after discontinuation among otherwise healthy men with overweight or obesity, a speaker reported.At ObesityWeek, Rajamannar Thennati, PhD, a researcher in high impact innovation – sustainable health solutions for Sun Pharmaceutical Industries,